These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 19710147)

  • 1. High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment.
    Gonzalez VD; Falconer K; Blom KG; Reichard O; Mørn B; Laursen AL; Weis N; Alaeus A; Sandberg JK
    J Virol; 2009 Nov; 83(21):11407-11. PubMed ID: 19710147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dominant enrichment of phenotypically activated CD38(+) HLA-DR(+) CD8(+) T cells, rather than CD38(+) HLA-DR(+) CD4(+) T cells, in HIV/HCV coinfected patients on antiretroviral therapy.
    d'Ettorre G; Ceccarelli G; Serafino S; Giustini N; Cavallari EN; Bianchi L; Pavone P; Bellelli V; Turriziani O; Antonelli G; Stroffolini T; Vullo V
    J Med Virol; 2016 Aug; 88(8):1347-56. PubMed ID: 26765625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic immune activation in the T cell compartment of HCV/HIV-1 co-infected patients.
    Sandberg JK; Falconer K; Gonzalez VD
    Virulence; 2010; 1(3):177-9. PubMed ID: 21178437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HCV-specific T-cell responses in HIV/hepatitis C virus-coinfected patients on highly active antiretroviral therapy are comparable to those observed in hepatitis C virus-monoinfected individuals.
    Rallón NI; Soriano V; Restrepo C; García-Samaniego J; Labarga P; López M; Peris A; González-Lahoz J; Benito JM
    J Acquir Immune Defic Syndr; 2011 May; 57(1):1-8. PubMed ID: 21786458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of T-cell responses to hepatitis C virus (HCV) during pegylated interferon plus ribavirin treatment in HCV-monoinfected and in HCV/HIV-coinfected patients.
    Capa L; Soriano V; García-Samaniego J; Nuñez M; Romero M; de Mendoza C; Cascajero A; Muñoz F; González-Lahoz J; Benito JM
    Antivir Ther; 2007; 12(4):459-68. PubMed ID: 17668554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T cell receptor excision circles (TRECs), CD4+, CD8+, and their CD45RO+, and CD45RA+, subpopulations in hepatitis C virus (HCV)-HIV-co-infected patients during treatment with interferon alpha plus ribavirin: analysis in a population on effective antiretroviral therapy.
    Arizcorreta A; Márquez M; Fernández-Gutiérrez C; Guzmán EP; Brun F; Rodríguez-Iglesias M; Girón-González JA
    Clin Exp Immunol; 2006 Nov; 146(2):270-7. PubMed ID: 17034579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD4 T lymphocyte proliferative responses to hepatitis C virus (HCV) antigens in patients coinfected with HCV and human immunodeficiency virus who responded to anti-HCV treatment.
    Legrand E; Neau D; Galperine T; Trimoulet P; Moreau JF; Pitard V; Lacut JY; Ragnaud JM; Dupon M; Le Bail B; Bernard N; Schvoerer E; Houghton M; Fleury H; Lafon ME
    J Infect Dis; 2002 Aug; 186(3):302-11. PubMed ID: 12134226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of hepatitis C virus coinfection on immune restoration during successful antiretroviral therapy in chronic human immunodeficiency virus type 1 disease.
    Santin M; Mestre M; Shaw E; Barbera MJ; Casanova A; Niubo J; Bolao F; Podzamczer D; Gudiol F
    Eur J Clin Microbiol Infect Dis; 2008 Jan; 27(1):65-73. PubMed ID: 17938979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modelling CD4 T Cell Recovery in Hepatitis C and HIV Co-infected Children Receiving Antiretroviral Therapy.
    Majekodunmi AO; Thorne C; Malyuta R; Volokha A; Callard RE; Klein NJ; Lewis J;
    Pediatr Infect Dis J; 2017 May; 36(5):e123-e129. PubMed ID: 28403051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study.
    Dieterich D; Rockstroh JK; Orkin C; Gutiérrez F; Klein MB; Reynes J; Shukla U; Jenkins A; Lenz O; Ouwerkerk-Mahadevan S; Peeters M; De La Rosa G; Tambuyzer L; Jessner W
    Clin Infect Dis; 2014 Dec; 59(11):1579-87. PubMed ID: 25192745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Could a loss of memory T cells limit responses to hepatitis C virus (HCV) antigens in blood leucocytes from patients chronically infected with HCV before and during pegylated interferon-alpha and ribavirin therapy?
    Lee S; Hammond T; Watson MW; Flexman JP; Cheng W; Fernandez S; Price P
    Clin Exp Immunol; 2010 Jul; 161(1):118-26. PubMed ID: 20408862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C.
    Cramp ME; Rossol S; Chokshi S; Carucci P; Williams R; Naoumov NV
    Gastroenterology; 2000 Feb; 118(2):346-55. PubMed ID: 10648463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegylated Interferon-α-Induced Natural Killer Cell Activation Is Associated With Human Immunodeficiency Virus-1 DNA Decline in Antiretroviral Therapy-Treated HIV-1/Hepatitis C Virus-Coinfected Patients.
    Hua S; Vigano S; Tse S; Zhengyu O; Harrington S; Negron J; Garcia-Broncano P; Marchetti G; Genebat M; Leal M; Resino S; Ruiz-Mateos E; Lichterfeld M; Yu XG
    Clin Infect Dis; 2018 Jun; 66(12):1910-1917. PubMed ID: 29272392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-lymphocyte populations in hepatitis C and HIV co-infected patients treated with interferon-alfa-2a and ribavirin.
    Neau D; Galpérine T; Legrand E; Pitard V; Neau-Cransac M; Moreau JF; Ragnaud JM; Dupon M; Fleury H; Lafon ME
    HIV Med; 2003 Apr; 4(2):120-6. PubMed ID: 12702132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HCV coinfection does not alter the frequency of regulatory T cells or CD8+ T cell immune activation in chronically infected HIV+ Chinese subjects.
    Zhuang Y; Wei X; Li Y; Zhao K; Zhang J; Kang W; Sun Y
    AIDS Res Hum Retroviruses; 2012 Sep; 28(9):1044-51. PubMed ID: 22214236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of lymphoma in HIV-HCV-infected patients. Modifications in function of the anti-hepatitis C virus therapy.
    Gutiérrez-Saborido D; Gutiérrez-Valencia A; González Domenech CM; López Ruz MÁ; Raffo Márquez M; Omar M; Girón-González JA;
    Ann Hematol; 2019 Aug; 98(8):1953-1959. PubMed ID: 31025161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short communication: impact of hepatitis C viral clearance on CD4+ T-lymphocyte course in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin.
    Milazzo L; Foschi A; Mazzali C; Viola A; Ridolfo A; Galli M; Antinori S
    AIDS Res Hum Retroviruses; 2012 Sep; 28(9):989-93. PubMed ID: 22220723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in T-cell subsets in HIV-HCV-coinfected patients during pegylated interferon-alpha2a plus ribavirin treatment.
    Massanella M; Tural C; Papagno L; Garcia E; Jou A; Bofill M; Autran B; Clotet B; Blanco J
    Antivir Ther; 2010; 15(3):333-42. PubMed ID: 20516553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report.
    Zylberberg H; Benhamou Y; Lagneaux JL; Landau A; Chaix ML; Fontaine H; Bochet M; Poynard T; Katlama C; Pialoux G; Bréchot C; Pol S
    Gut; 2000 Nov; 47(5):694-7. PubMed ID: 11034587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C.
    Benito JM; García-Samaniego J; García M; Madejón A; Martín-Carbonero L; Cabello A; Álvarez B; Górgolas M; Rallón N
    J Interferon Cytokine Res; 2017 Jun; 37(6):278-286. PubMed ID: 28440692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.